Dr. Kenneth L. Blad, M.D.
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 550
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
NE license 21848
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The Nebraska Medical Center Omaha, NE
- Chi Health Bergan Mercy Omaha, NE
- The Nebraska Methodist Hospital Omaha, NE
- Chi Health Lakeside Omaha, NE
- Nebraska Orthopaedic Hospital Omaha, NE
Medical groups
- Midwest Regional Health Services LLC (13 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 550
- Services billed
- 3,379
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 427 | 350 |
| Established patient office or other outpatient visit, 20-29 minutes | 371 | 191 |
| Insertion of needle into vein for collection of blood sample | 303 | 203 |
| Blood test, comprehensive group of blood chemicals | 254 | 195 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 206 | 162 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 174 | 174 |
| Annual depression screening, 5 to 15 minutes | 173 | 173 |
| Blood test, lipids (cholesterol and triglycerides) | 170 | 158 |
| Established patient office or other outpatient visit, 40-54 minutes | 121 | 96 |
| Blood test, thyroid stimulating hormone (tsh) | 117 | 93 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 26 companies reported 60 payments worth $1,205 in total to this clinician.
| AbbVie Inc. | $259 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $173 |
| Otsuka America Pharmaceutical, Inc. | $103 |
| Sumitomo Pharma America, Inc. | $85.86 |
| Lilly USA, LLC | $64.82 |
| Novo Nordisk Inc | $59.92 |
| Bayer HealthCare Pharmaceuticals Inc. | $43.74 |
| Abbott Laboratories | $43.20 |
| Food and Beverage | $1,205 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $144,968 in research payments for these studies, mostly to the institutions running them.
- Roche Cancer Screening Collection Study
Genentech, Inc. - A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Diseas…
AstraZeneca Pharmaceuticals LP - Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
ModernaTX, Inc. · Completed · NCT05827978 - NB (Contrave) Cardiovascular Outcomes Trial
Currax Pharmaceuticals LLC - A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT05330975 - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.